SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Time elapses in achieving the goal. Deadline. Get off schedule. Make it before the end of the term. Overdue work. Loss of relevance. Decrease in achievements, obsolescence of tasks.
Gene therapy
Regenxbio’s Hunter Syndrome Gene Therapy Hit With 3-Month PDUFA Delay
The FDA has postponed its decision date for Regenxbio’s Hunter syndrome gene therapy to review additional longer-term clinical data for the asset.
August 19, 2025
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage. Businessmen, employees walking into open door symbolizing new opportunities. Way to success. Concept of business, promotion, motivation, ambitions and ideas
Immuno-oncology
Genentech Walks Away From $2B Partnership With Adaptive Biotechnologies
Adaptive and Genentech first partnered in 2018 to advance T cell receptor-based therapies for cancer.
August 19, 2025
 · 
1 min read
 · 
Tristan Manalac
A human hand and a robot hand shake hands over a white circle on a green background
Collaboration
VantAI Links With Halda in Potential $1B+ Proteomics Pact
VantAI will use its machine learning capabilities to identify novel target-effector pairs that Halda can use in designing its bifunctional small-molecule drugs.
August 19, 2025
 · 
2 min read
 · 
Tristan Manalac
Hands in black and white dropping a collection of pills on a pink background
Manufacturing
Oral Wegovy’s Pending Approval Puts Spotlight on Viability of High-Dose Peptides
While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured investors it has the manufacturing capacity to roll out oral semaglutide without restrictions on supply.
August 19, 2025
 · 
5 min read
 · 
Nick Paul Taylor
FDA
Leaked MAHA Strategy Emphasizes Vaccine Overhaul, Streamlined Access to Novel Therapies
A draft copy of the Make America Healthy Again Commission’s latest report, obtained by Politico, focuses on vaccine-related injuries and expediting access to investigational medicines for children—even though the FDA has recently rejected several of them.
August 18, 2025
 · 
3 min read
 · 
Heather McKenzie
Darmstadt, Germany - November 10, 2021: A building at the headquarters of science and technology company Merck KGaA.
Neuroscience
Merck KGaA Drops up to $2B in Skyhawk Collab for RNA-Targeting Tech
Waltham, Massachusetts–based Skyhawk Therapeutics has been collecting collaborations with larger companies in spades since launching in 2018.
August 18, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
shopping cart loaded with pills with dollar signs around it on a light blue background
GLP-1
Novo Teams Up With GoodRx for Lower-Price GLP-1s, Giving DTC Another Shot
Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip insurance. This is not the first time Novo has partnered with a pharmacy to offer the blockbuster drugs.
August 18, 2025
 · 
1 min read
 · 
Annalee Armstrong
Poster sketch image artwork photo collage of body language finger showing gesture symbol thumb down dislike dissatisfied minus no opinion.
Sickle cell disease
Pfizer’s $5.4B GBT Bet Disappoints Again as Sickle Cell Therapy Fails in Phase III
Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain episodes in patients with sickle cell disease over the 48-week treatment period.
August 18, 2025
 · 
2 min read
 · 
Tristan Manalac
A piggy bank crammed with $100 bills on a background of American cash
Funding
Gene Therapy Specialist Kriya Raises $313M
Kriya is advancing a host of gene therapies for a wide variety of chronic diseases, including geographic atrophy, trigeminal neuralgia and type 1 diabetes.
August 18, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS